09/29/2020 | Press release | Distributed by Public on 09/29/2020 01:23
Data confirming the promise of THR-687 in treating DME and other retinal vison-threatening retinal diseases, and charactarization of a preclinical model for testing and developing drug candidates for different stages of dryAMD
Leuven, Belgium , 29 September 2020 - 8.00 A.M. CET - Oxurion NV (Euronext Bxls: OXUR), a biopharmaceutical company developing next generation standard-of-care therapies for diabetic macular edema (DME), announces today that it will present new pre-clinical data on THR-687 at the EURETINA 2020 Virtual Meeting taking place October 2-4 th. The European Society of Retina Specialists (EURETINA) was established over 20 years ago and hosts the leading annual European retinal congress which now attracts over 5,000 vitreoretinal and macular specialists.
The company will make two presentations on pre-clinical data at the meeting as follows (sessions are virtual so have no allocated time slots):
1. Title: THR-687, a potent pan-RGD integrin antagonist, holds promise as next-generation therapy for diabetic macular edema (DME)
2. Title: Characterization of the acute rat model of sodium iodate-induced dry age-related macular degeneration (dryAMD)
Details of the abstracts can be found on the EURETINA 2020 Virtual website: https://www.euretina.org/congress/amsterdam-2020/virtual-2020-freepapers/